search
Back to results

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment ((KISV))

Primary Purpose

Smoking Cessation

Status
Recruiting
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Bupropion
Sponsored by
University of Kansas Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Smoking Cessation

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: African American age >18 years interested in quitting smoked >1 cpd for >1 years smoked on >25 days in the past month willing to take 6 months of study medication and complete all visits have a home address and functioning telephone number Exclusion Criteria: Consistent with contraindications for bupropion: use of psychoactive medications history of alcohol or substance abuse within the past year binge drinking (>5 drinks on one occasion) >2 times in the past month history of seizures or head trauma; history of bulimia or anorexia nervosa pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding myocardial infarction in the past 2 months reported use of opiates, cocaine, or stimulants unstable diabetes bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded. use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days planning to move from the Kansas City area in the next year other smoker in household enrolled in the study.

Sites / Locations

  • University of Kansas Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Standard Treatment

Extended Treatment

Arm Description

250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.

Outcomes

Primary Outcome Measures

Verified abstinence at Month 6
Participants receiving extended bupropion treatment will have significantly higher Month 6 verified point-prevalence abstinence than participants receiving standard bupropion treatment.

Secondary Outcome Measures

Adherence to medication
We will evaluate the concordance of a biological sample of bupropion level, observable pill count, and 3-day recall as measurements of medication adherence.

Full Information

First Posted
February 7, 2023
Last Updated
February 28, 2023
Sponsor
University of Kansas Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05732272
Brief Title
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
Acronym
(KISV)
Official Title
Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 28, 2023 (Actual)
Primary Completion Date
November 30, 2025 (Anticipated)
Study Completion Date
March 30, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Kansas Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will evaluate the efficacy of extended bupropion(6 months) versus standard bupropion treatment (7 weeks) among African American daily smokers.
Detailed Description
The primary objective of this study is to evaluate extended use of bupropion with the goal of enhancing abstinence in African American daily smokers, including the full spectrum of light, moderate, and heavy smokers. A two-arm, randomized design will be used to evaluate the efficacy of extended (6 months) bupropion treatment compared to standard (7 weeks) bupropion treatment. Baseline randomization stratified by gender and cpd (≤10, >10cpd) will assign participants (N=500) to receive extended treatment (EXT; 24 weeks of bupropion, n=250) or standard treatment (ST; 7 weeks of bupropion, n=250). All participants will receive culturally-relevant, individualized smoking cessation counseling, including support for medication adherence, and will be followed through Month 12.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking Cessation

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard Treatment
Arm Type
Active Comparator
Arm Description
250 participants will be randomly assigned to the standard treatment arm and receive 7 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 7 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
Arm Title
Extended Treatment
Arm Type
Active Comparator
Arm Description
250 participants will be randomly assigned to the extended treatment arm and receive 24 weeks of bupropion SR following standard dosing guidelines(150 mg once daily for 3 days, then 150mg twice daily for 24 weeks). Participants in this arm will also receive 8 smoking cessation counseling sessions consistent with the Clinical Practice Guidelines.
Intervention Type
Drug
Intervention Name(s)
Bupropion
Intervention Description
150 mg once daily for 3 days, then twice daily for the remainder of the treatment phase.
Primary Outcome Measure Information:
Title
Verified abstinence at Month 6
Description
Participants receiving extended bupropion treatment will have significantly higher Month 6 verified point-prevalence abstinence than participants receiving standard bupropion treatment.
Time Frame
Month 6
Secondary Outcome Measure Information:
Title
Adherence to medication
Description
We will evaluate the concordance of a biological sample of bupropion level, observable pill count, and 3-day recall as measurements of medication adherence.
Time Frame
Week 4

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: African American age >18 years interested in quitting smoked >1 cpd for >1 years smoked on >25 days in the past month willing to take 6 months of study medication and complete all visits have a home address and functioning telephone number Exclusion Criteria: Consistent with contraindications for bupropion: use of psychoactive medications history of alcohol or substance abuse within the past year binge drinking (>5 drinks on one occasion) >2 times in the past month history of seizures or head trauma; history of bulimia or anorexia nervosa pregnant (as measured by over the counter pregnancy test kit for women of child-bearing age only) or contemplating pregnancy; breast feeding myocardial infarction in the past 2 months reported use of opiates, cocaine, or stimulants unstable diabetes bupropion is a known inhibitor of the liver enzyme CYP2D6, so those taking drugs known to be higher metabolized by this enzyme (e.g., metoprolol, tamoxifen) will be excluded. use of stop smoking medications (bupropion, varenicline, nicotine replacement, fluoxetine, clonidine, buspirone, or doxepin) in the past 30 days planning to move from the Kansas City area in the next year other smoker in household enrolled in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tricia Snow, MPH
Phone
816-398-8960
Email
psnow@kumc.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lisa Sanderson Cox, PhD
Organizational Affiliation
University of Kanas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Kansas Medical Center
City
Kansas City
State/Province
Missouri
ZIP/Postal Code
64130
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tricia Snow, MPH
Phone
816-398-8960
Email
psnow@kumc.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment

We'll reach out to this number within 24 hrs